Last reviewed · How we verify
NCT05282251
Intrapleural Nebulization of Bupivacain to Reduce Postoperative Pain
NA trial testing Intrapleural bupivacine nebulization in Lung Diseases in 60 participants. Currently enrolling.
15 July 2024
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 17 May 2024 |
| Primary completion | 15 July 2024 |
| Estimated completion | 15 July 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Intrapleural bupivacine nebulization — full drug profile →
- Intravenous paracetamol and ketorolac — full drug profile →
Conditions studied
- Lung Diseases — all drugs for Lung Diseases →
Sponsor
Assiut University
Who can join
Adults 18 to 70, any sex, with Lung Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thoracic surgery is now common and as other surgeries evolution of minimally invasive techniques is employed. Video-assisted thoracic surgery (VATS) produces little scar but may produce severe pain that may affect the pulmonary function. Many procedure was developed like intercostal nerve block which require injections at multiple levels, Insertion of local anaesthetic (LA) in the surgical drain but that was dangerous due to the large amount of LA and not sufficient to completely eliminate pain. Bupvicaine nebulization, through surgical port which won't make any other wound, thought to be sufficient because Nebulization will enable us better distribution and less amounts of LA. Bupvicaine is local anaesthetic amide group that works by blocking sodium channels thus preventing progression of action potential.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05282251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Diseases
Currently open trials in the same condition.
- NCT07356076 — The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases · recruiting
- NCT07243964 — Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation · recruiting
- NCT07270744 — Data Collection Using Eko Devices in a Clinical Setting · recruiting
- NCT07227376 — Data Collection Using Eko Digital Devices in a Clinical Setting · recruiting
- NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05282251 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 20 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05282251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing